Articles related to PATIENT SAFETY

Two large scale studies featured in The British Medical Journal concluded that mRNA-based vaccines do not appear to be associated with an increased risk of neurological adverse events; and secondly, that risks of Guillain-Barré syndrome and Bell’s palsy are slightly increased after immunization. Overall, the findings of both studies are reassuring about the safety of the vaccines, particularly compared with the observed risks associated with SARS-CoV-2 infection.

The U.S. Food and Drug Administration (FDA) held a two-day public meeting to discuss managing the potential side effects of gene therapies following the death of a boy with a rare neuromuscular disease. High doses of gene therapies are known to cause liver damage, and recent studies have also found a potential long-term cancer risk in mice and dogs treated with gene therapies.

Findings: Primary outcomes included AMI, HF, stroke, and CVEs; 51 secondary and safety outcomes included angioedema, cough, syncope, and electrolyte abnormalities. ACE inhibitors were associated with a significantly increased risk of four secondary and safety outcomes compared with ARBs.Design: Multinational cohort study; Patients: ~2.3M ACE, ~674K ARB